Sleep EEG effects of 3,4-methylenedioxyethamphetamine (MDE; "eve") in healthy volunteers.
E Gouzoulis, A Steiger, M Ensslin, A Kovar, L Hermle
Biological Psychiatry December 15, 1992 DOI: 10.1016/0006-3223(92)90191-2 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Double-blind, placebo-controlled, cross-over sleep EEG study Peer reviewed |
|---|---|
| Sample size | 6 |
| Population | Healthy volunteers |
| Intervention | MDE |
| Dose | 140 mg |
| Duration | Sleep EEG recorded from 11 PM to 7 AM the next morning |
| Measures | sleep electroencephalogram (EEG) |
| Key points | MDE (140 mg) given at 11 PM caused all six participants to wake 60-120 minutes after dosing and stay awake at least 150 minutes, reducing total sleep time and increasing intermittent wakefulness relative to placebo (p < 0.001). After returning to sleep, REM sleep was completely suppressed (p < 0.001). The authors state these effects largely demonstrate MDE's stimulant, amphetamine-like properties. |
Abstract
3,4-methylenedioxyethamphetamine (MDE; "Eve") exerts similar psychotropic effects in humans as 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy") and is less toxic in animal studies. We conducted a double-blind, placebo-controlled, cross-over sleep electroencephalogram (EEG) study with healthy volunteers. One hundred forty milligrams of MDE or placebo were administered PO in six subjects at 11 PM. Sleep EEG was registered from 11 PM-7 AM the next morning. All subjects had a normal sleep onset latency. They all awoke 60 to 120 min after administration of MDE and stayed awake for at least 150 min (total sleep time, TST MDE < placebo and intermittent time awake MDE > placebo: p < 0.001). After again falling asleep rapid eye movement (REM) sleep was totally suppressed (REM during time in bed, TIB MDE < placebo: p < 0.001). A cyclic alternation of relatively long periods of slow wave sleep (SWS) with periods of light sleep occurred in three subjects during the second part of the night (stage 4 in second part of night MDE > placebo: p = 0.16). The effects of MDE on sleep variables largely demonstrate the stimulant, amphetamine-like properties of MDE.
Citations in the library
Cited by 7
- Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d -methamphetamine in healthy volunteers Psychopharmacology February 18, 1999
- Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers Psychopharmacology November 20, 2007
- The Neuropsychopharmacology and Toxicology of 3,4‐methylenedioxy‐N‐ethyl‐amphetamine (MDEA) CNS Drug Reviews June 1, 2004
- Effects of acute 3,4-methylenedioxymethamphetamine on sleep and daytime sleepiness in MDMA users: a preliminary study. Sleep November 2009
- Altered states: the clinical effects of Ecstasy. Pharmacology & Therapeutics April 2003
and 2 more in the library
Cites 18
- Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens Journal of Psychoactive Drugs October 1, 1986
- Subjective Reports of the Effects of MDMA in a Clinical Setting Journal of Psychoactive Drugs October 1, 1986
- Hallucinogenic Amphetamine Selectively Destroys Brain Serotonin Nerve Terminals Science September 6, 1985
- The Background and Chemistry of MDMA Journal of Psychoactive Drugs October 1, 1986
- Can Drugs Be Used to Enhance the Psychotherapeutic Process? American Journal of Psychotherapy July 1, 1986
and 13 more in the library